Robocath SAS
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Robocath SAS - overview
Established
2009
Location
Roubaix, -, France
Primary Industry
Medical Devices & Equipment
About
Robocath SAS specializes in advanced robotic solutions for interventional vascular medicine, enhancing the precision and efficiency of coronary procedures with its flagship product, R-One™. Robocath SAS, founded in 2009 and headquartered in Roubaix, France, focuses on the development of robotic systems for percutaneous coronary interventions. Philippe Bencteux is the founder, who has a history in deep tech entrepreneurship. The company raised EUR 17 million in VENTURE DEBT financing in January 2022, which represents the total amount raised to date, totaling USD 9.
00 mn over 9 deals. Robocath specializes in designing, developing, and commercializing robotic solutions aimed at improving interventional vascular medicine. Its flagship product, R-One™, assists in percutaneous coronary interventions (PCI) with bionic technology to enhance procedure precision. The system features an intuitive control unit and compatibility with leading market devices, targeting healthcare professionals like interventional cardiologists across Europe, Africa, and China.
In 2022, Robocath generated revenue of USD 766,131. 80, while reporting an EBITDA of USD -7,906,115. 70, reflecting the company's investment in its growth and product development. Looking forward, Robocath plans to leverage its recent VENTURE DEBT financing raised in January 2022 to support the launch of new products designed to enhance existing robotic solutions.
The company is also targeting expansion into new markets, with specific focus on increasing its presence in Asia and North America by 2025. These strategic initiatives aim to broaden the adoption of its technologies in the global healthcare landscape.
Current Investors
Go Capital, M Capital, Normandie Participations
Primary Industry
Medical Devices & Equipment
Sub Industries
Biotechnology, Surgical Devices, Diagnostic Equipment
Website
www.robocath.com
Verticals
HealthTech, Robotics
Company Stage
Series C
Total Amount Raised
Subscriber access only
Robocath SAS - timeline of key events
Robocath SAS - financials
| Fiscal Year Ended | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | 501,600 | 1,583,580 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | 215.7% | - | - | - |
| EBITDA (USD) | (829,806) | - | - | - | (3,816,123) | (5,678,492) | - | - | - |
| Operating Income (USD) | (864,242) | - | - | - | (4,006,031) | (7,809,649) | - | - | - |
| Operating Margin | - | - | - | - | (798.7%) | (493.2%) | - | - | - |
| % EBITDA Margin | - | - | - | - | (760.8%) | (358.6%) | - | - | - |
| NET Income (USD) | (1,271,567) | - | - | - | (3,814,221) | (7,049,082) | - | - | - |
| % Net Margin | - | - | - | - | (760.4%) | (445.1%) | - | - | - |
Robocath SAS - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.